Incidence of Post-Liver Transplant Hepatic Dysfunction After Sustained Virologic Response Following Direct-Acting Anti-Hepatitis C Therapy | Zendy

Ashokkumar Jain | Zendy; Thomas Riley | Zendy; Karen Krok | Zendy; Ian Schreibman | Zendy; Dipti M. Karamchandani | Zendy; Xiaojie Liao | Zendy; Ye Tian | Zendy; Takehiko Dohi | Zendy; Zakiyah Kadry | Zendy

Open Access

Incidence of Post-Liver Transplant Hepatic Dysfunction After Sustained Virologic Response Following Direct-Acting Anti-Hepatitis C Therapy

Author(s) -

Ashokkumar Jain,

Thomas Riley,

Karen Krok,

Ian Schreibman,

Dipti M. Karamchandani,

Xiaojie Liao,

Ye Tian,

Takehiko Dohi,

Zakiyah Kadry

Publication year - 2020

Publication title -

experimental and clinical transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.321

H-Index - 29

ISSN - 1304-0855

DOI - 10.6002/ect.2018.0127

Subject(s) - medicine , immunosuppression , gastroenterology , alanine transaminase , incidence (geometry) , hepatitis c , liver function , bilirubin , physics , optics

Newly developed, direct-acting antiviral therapy is effective in over 90% of cases to eradicate hepatitis C virus infection. Direct-acting antiviral therapy is also effective in liver transplant recipients with recurrent hepatitis C virus infection. However, hepatic function after sustained virologic response in transplant recipients is unknown. Here, we aimed to uncover the incidence of hepatic dysfunction in this patient group at our center.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research